[
  {
    "image": "scihub_s00784-003-0233-4.pdf_1.jpg",
    "pred": "53\nTable 1 Clinical data (Rec recurrence, Met metastasis, Pr primary,\nTmf temporomandibular fossa, Smr submandibular region, S\ntumor unresectable, L regional lymph node metastasis, D distant\nsurgery, R radiation therapy, C chemotherapy, UR primary site of\nmetastasis, Ao alive without disease, Ac alive with disease, Dc died\nof disease)\nCase\nDiagnosis\nCase\nSex\nAge\nSite\nTreatment\nRec\nMet\nFollow-up\nStatus\nno.\n(years)\n1\nOsteosarcoma\nPr\nM\n25\nTmf\nS+R+C\n7 years 1 month\nAo\n2\nOsteosarcoma\n−\n| |\nPr\nF\n34\nMaxilla\nS\n9 years 6 months\nAo\n3\nOsteosarcoma\nPr\nF\n40\nMandible\nS\nIDD\n6 years 4 months\nAo\n4\nOsteosarcoma\nPr\nM\n46\nMandible\nS\n5 years\nDc\n5\nOsteosarcoma\nPr\nM\n50\nMandible\ns\n13 years 7 months\nAc\n6\nOsteosarcoma\nPr\nM\n50\nMaxilla\nS+C\n3 years 2 months\nAo\n7\nOsteosarcoma\nRec\nM\n56\nMaxillary sinus\nS+R+C\n4 years 1 month\nDc\n8\nOsteosarcoma\nRec\nF\n63\nMaxilla\nS+R+C\n\nD\n3 years 3 months\nDc\n9\nOsteosarcoma\nRec\nM\n67\nMandible\nS\n9 years 3 months\nAo\n| + +\n\n10\nMFH\nPr\nM\n29\nMaxillary sinus\nS+C\n1 year 4 months\nDc\n11\nMFH\nPr\nM\n43\nMandible\nS\n2 years\nDc\n12\nMFH\nPr\nM\n45\nSmr\nS+R\n8 years 1 month\nAo\n13\nMFH\nRec\nM\n48\nMandible\nS\n4 years 6 months\nAo\n14\nMFH\nPr\nM\n56\nMaxilla\nS+R+C\n11 years 8 months\nAo\n15\nMFH\nPr\nM\n57\nMaxillary sinus\nS\nL\n9months\nDc\n16\nMFH\nPr\nM\n63\nMaxillary sinus\nS+R+C\n5 years\nAo\n17\nRhabdomyosarcoma\nPr\nM\n11\nBuccal mucosa\nS\n+\n17 years 3 months\nAo\n18\nRhabdomyosarcoma\nPr\nF\n27\nBuccal mucosa\nS+R+C\nD\n1year 6 months\nDc\n19\nRhabdomyosarcoma\nPr\nM\n55\nMaxilla\nS+C\nD\n2 years 3 months\nDc\n20\nRhabdomyosarcoma\nM\n58\nMaxilla\nC+R\nUR\nL+D\n4 months\nDc\nPr\n21\nRhabdomyosarcoma\nM\n77\nMandible\nS\n2 years 9 months\nAo\nPr\n22\nFibrosarcoma\nF\nb5m\nMandible\nS+C\n9 years 9 months\nAo\nPr\n23\nFibrosarcoma\nPr\nF\n10\nMandible\nS\n11 years 6 months\nAo\n24\nS\n19 years\nAo\nFibrosarcoma\nPr\nF\n16\nMandible\n25\nM\n53\nS+R\n14 years\nAo\nPlasmacytoma\nPr\nMandible\nMaxillary sinus\nS+R\n5 years 1 month\nAo\n26\nPlasmacytoma\nPr\nM\n59\n27\nM\n25\nMaxilla\nC+R\nUR\nL+D\n2 months\nDc\nLeiomyosarcoma\nRec\nM\n43\nMandible\nS\nD\n8 years\nAc\n28\nLeiomyosarcoma\nPr\nTmf\nC+R\nUR\n4 years\nDc\n29\nAngiosarcoma\nPr\nM\n34\n—\n53\nMaxilla\nS+R\nL\n8months\nDc\n30\nAngiosarcoma\nPr\nM\n+\nF\n33\nBuccal mucosa\nS\n2 years 10 months\nDc\n31\nLiposarcoma\nPr\n+\nM\n31\nMandible\nS\n5 months\nDc\n32\nAmeloblastic fibro-\nRec\n+\nsarcoma\nThe most common histological type was osteosarcoma (n=9; 28%),\nthe temporomandibular fossa. The survival rate and survival curve\nfollowed by malignant fibrous histiocytoma (MFH;(n=7, 22%),\nwere calculated by the Kaplan-Meier method using SPSS for\nrhabdomyosarcoma (n=5, 16%), fibrosarcoma (n=3, 9%), plasma-\nWindows, version 10.\ncytoma (n=2, 6%), leiomyosarcoma (n=2, 6%), angiosarcoma (n=2,\n6%), and liposarcoma (n=1, 3%), ameloblastic fibrosarcoma (n=1,\n3%). The histological subtypes of osteosarcoma were chondrob-\nResults\n1astic (n=5; Table 1, nos. 1, 2, 6, 8, 9), osteoblastic (n=3, nos. 3, 4,\n7), and telangiectatic (n=1, no. 5). In rhabdomyosarcoma, the\nhistological subtypes were alveolar (n=3, nos. 17, 18, 20) and\nFourteen patients of 32 were making satisfactory progress\npleomorphic (n=2, nos. 19, 21). Patients with malignant lymphoma\nwithout local recurrence or metastasis at a mean follow-up\nwere excluded from this study because malignant lymphoma is a\nperiod of 8.5 years, ranging from 2 years 3 months to\nsystemic disease. Two cases of plasmacytoma were both of the\n19 years. Local recurrence was found in 10 cases (31%)\nsolitary type, therefore these cases were included.\nSurgical resection (S) alone was carried out in 15 patients.\nand metastasis in 11 (34%). Among 10 patients with local\nTriple modality of S, radiation therapy (R) and chemotherapy (C)\nrecurrence, 3 are alive after 617 years, and 7 died of their\nwas performed in 6, combined therapy of S/C in 4, and S/R was in\ntumors after 5 months to 4 years. Among the 3 patients\n4. We judged that the primary tumors were unresectable in three\nalive, one (no. 3) was treated by surgery and the other (no.\ncases; therefore combined therapy of R and C was given to these 3\npatients. Radiation therapy was given preoperatively in 6 cases,\n17) by surgery and postoperative radiation therapy (50 Gy)\npostoperatively in 3 and both in 1. The doses used varied from 18 to\nafter local recurrence was found. These two patients are\n80 Gy, with an average of 48 Gy. All radiation therapy was external\nalive without evidence of disease over 3 years and 7 years\nirradiation. The fraction sizes were 2.5 Gy, treating 4 days in a\nafter salvage treatment. Another patient (no. 5) was treated\nweek. Chemotherapy was given preoperatively in 8 cases and\npostoperatively in 2. The chemotherapy regimens were varied.\nby preoperative radiation therapy (45 Gy) and surgery for\nTreatment was determined according to the experience of the\nlocal recurrence. The local recurrence was controlled, but\nsurgeon. This resulted in a lack of unity in the treatment protocol.\nthis patient developed distant metastasis to the lung.\nThe common agents were cisplatin (n=5), 5-fluorouracil (n=4), and\nThe 5-year survival rate of patient with local recurrence\ndoxorubicin (n=4). The regional intra-arterial infusion chemother-\nwas 30% (Fig. 1). Among 11 patients with metastases 9 died\napy administered via the superficial temporal artery was given in 9\nof 11 patients who had sarcoma of the maxilla, maxillary sinus, or"
  }
]